Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ADAP

Adaptimmune Therapeutics Plc ADR

Oct 27 • 04:00PM ET

0.0502

0.0000 0.00 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: IOVA FATE ALLO ADPT BLRX CGEN AFMD IMTX TPST

Index	-	P/E	-	EPS (ttm)	-0.66	Insider Own	0.63%	Shs Outstand	265.05M	Perf Week	-22.41%
Market Cap	13.31M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	-98.04%	Shs Float	-	Perf Month	-61.09%
Enterprise Value	-	PEG	-	EPS next Q	-0.12	Inst Own	31.23%	Short Float	-	Perf Quarter	-36.70%
Income	-	P/S	-	EPS this Y	-96.74%	Inst Trans	-	Short Ratio	0.28	Perf Half Y	-82.44%
Sales	-	P/B	-	EPS next Y	-5.73%	ROA	-	Short Interest	31.38M	Perf YTD	-90.68%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	0.86 -94.16%	Perf Year	-92.87%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	34.83% -	ROIC	-	52W Low	0.02 148.51%	Perf 3Y	-96.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	207.12% -	Gross Margin	-	Volatility	55.31% 34.38%	Perf 5Y	-98.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-93.14%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-99.48%
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-53.61%	Profit Margin	-	RSI (14)	37.50	Recom	3.33
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-57.94%	Beta	2.39	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-89.30%	SMA50	-51.13%	Rel Volume	0.00	Prev Close	0.05
Employees	506	LT Debt/Eq	-	Earnings	Aug 13 BMO	SMA200	-81.26%	Avg Volume	110.30M	Price	0.05
IPO	May 06, 2015	Option/Short	No / No	EPS/Sales Surpr.	52.38% 59.05%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-25	Downgrade	Mizuho	Outperform → Neutral	$0.50
Jul-30-24	Initiated	H.C. Wainwright	Buy	$4
May-30-24	Initiated	Scotiabank	Sector Outperform	$3.15
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Oct-20-25 07:40AM	Adaptimmune Announces Delisting from Nasdaq (Newsfile) -70.51%
Aug-13-25 07:30AM	Adaptimmune Reports Q2 Financial Results and Provides Business Update (Newsfile)
Aug-04-25 04:00PM	US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel (PR Newswire) +19.92%
Jul-28-25 07:30AM	Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds (Newsfile) -71.17%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
03:05AM	Loading…
May-14-25 03:05AM	Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ... (GuruFocus.com) +8.80%
May-13-25 07:30AM	Adaptimmune Reports Q1 Financial Results and Provides Business Update (Newsfile) -15.31%
May-12-25 09:48AM	What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings (GuruFocus.com)
May-07-25 12:00PM	Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 (Newsfile)
Mar-21-25 12:05PM	Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result (GuruFocus.com)
03:01AM	Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
Mar-20-25 12:10PM	Adaptimmune targets $400M sarcoma franchise peak sales by 2027 (SeekingAlpha) -37.65%
12:10PM	Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00AM	Adaptimmune Provides Q4 and Full Year 2024 Business Update (Newsfile)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha)
07:00AM	Loading…
Mar-18-25 07:00AM	From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines (FastCompany)
Mar-12-25 04:54PM	Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 (Newsfile)
Jan-30-25 04:00PM	Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 (Newsfile)
Jan-13-25 08:00AM	Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) (Newsfile)
Dec-19-24 07:30AM	Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK (Newsfile)
Dec-02-24 04:00PM	First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) (Newsfile)
Nov-15-24 05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
Nov-14-24 11:55AM	Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints (Pharmaceutical Technology) -23.28%
02:15AM	Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... (GuruFocus.com)
Nov-13-24 04:05PM	Adaptimmune Reports Q3 2024 Financial and Business Updates (Newsfile)
09:00AM	Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial (Newsfile)
Nov-05-24 09:19AM	Adaptimmune to Participate in Scientific and Medical Conferences this November and December (Newsfile)
Oct-31-24 05:20PM	Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024 (Newsfile) +10.23%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -5.41%
08:00AM	Loading…
Aug-28-24 08:00AM	Adaptimmune to Participate in Two Bank Conferences this September (Newsfile)
Aug-12-24 07:00AM	Adaptimmune Reports Q2 2024 Financial and Business Updates (Newsfile) +9.82%
Aug-09-24 07:13AM	Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval (Pharmaceutical Technology)
Aug-05-24 08:00AM	Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024 (Newsfile) -16.24%
Aug-02-24 11:53AM	Adaptimmunes Tecelra gains accelerated approval for synovial sarcoma (Pharmaceutical Technology) -7.87%
08:46AM	FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade (Benzinga)
06:54AM	First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer (BioPharma Dive)
Aug-01-24 08:20PM	Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor (Business Wire)
Jul-24-24 11:13PM	Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now? (Insider Monkey) +5.69%
Jul-03-24 11:11AM	3 Biotech Moonshots With Imminent Catalyst Potential (InvestorPlace)
06:00AM	5 FDA decisions to watch in the third quarter (BioPharma Dive)
Jun-03-24 12:00PM	Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise (Newsfile) -5.31%
May-31-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +11.88%
May-30-24 04:01PM	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications (GlobeNewswire)
04:01PM	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications (Newsfile)
May-17-24 06:49AM	Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating (MT Newswires) -7.50%
May-16-24 08:18AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-15-24 12:53PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +7.83%
11:07AM	Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital (MT Newswires)
07:30AM	Adaptimmune Reports Q1 2024 Financial and Business Updates (Newsfile)
07:00AM	Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital (Newsfile)
May-01-24 12:00PM	Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 (Newsfile)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire) +12.87%
Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05% -8.00%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks) +7.11%
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wood Gavin	Chief Financial Officer	Sep 02 '25	Sale	0.01	96,000	950	0	Sep 03 05:00 PM
Gavin Wood	Chief Financial Officer	Sep 02 '25	Proposed Sale	0.06	16,000	942		Sep 02 08:00 AM
Bertrand William C JR	Chief Operating Officer	Aug 28 '25	Sale	0.01	207,000	2,091	986,352	Aug 29 06:25 PM
William Bertrand	Chief Operating Officer	Aug 28 '25	Proposed Sale	0.06	34,500	2,070		Aug 29 06:24 PM
Behbahani Ali	Director	Aug 18 '25	Sale	0.01	14,671,794	176,062	0	Aug 19 07:07 PM
Behbahani Ali	Director	Aug 15 '25	Sale	0.01	4,828,206	53,110	14,671,794	Aug 19 07:07 PM
New Enterprise Associates, 14	Affiliate	Aug 15 '25	Proposed Sale	0.07	13,829,778	981,914		Aug 15 04:24 PM
New Enterprise Associates, 16	Affiliate	Aug 15 '25	Proposed Sale	0.07	3,250,000	230,750		Aug 15 04:23 PM
EcoR1 Capital, LLC	10% Owner	Jul 28 '25	Sale	0.11	33,931,740	3,817,321	130,492,680	Jul 30 06:20 PM
EcoR1 Capital, LLC	10% Owner	Jul 30 '25	Sale	0.10	27,433,338	2,800,944	100,371,882	Jul 30 06:20 PM
EcoR1 Capital, LLC	10% Owner	Jul 29 '25	Sale	0.10	2,687,460	271,971	127,805,220	Jul 30 06:20 PM
Norry Elliot	Chief Medical Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:16 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Sale	0.58	30,601	17,773	44,327	Jan 17 09:15 PM
Norry Elliot	Chief Medical Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 03:07 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:59 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:50 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Proposed Sale	0.58	30,601	17,772		Jan 17 02:42 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Sale	0.59	30,473	17,915	17,801	Jan 15 04:19 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 15 '25	Sale	0.57	29,096	16,724	41,582	Jan 15 04:19 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Sale	0.57	12,991	7,467	18,421	Jan 15 04:18 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Sale	0.59	12,392	7,285	5,845	Jan 15 04:17 PM
Norry Elliot	Chief Medical Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:17 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:16 PM
Lunger John	Chief Patient Supply Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:16 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 04:01 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Proposed Sale	0.57	12,991	7,467		Jan 15 03:55 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Proposed Sale	0.59	12,392	7,286		Jan 15 03:50 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 03:43 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Proposed Sale	0.59	30,473	17,917		Jan 15 03:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADAP

Adaptimmune Therapeutics Plc ADR

Upgrade your FINVIZ experience